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Abstract
Background
Lynch syndrome (LS) predisposes to endometrial cancer (EC), colorectal cancer, and other
cancers through inherited pathogenic variants affecting mismatch-repair (MMR) genes.
Diagnosing LS in women with EC can reduce subsequent cancer mortality through colono-
scopic surveillance and aspirin chemoprevention; it also enables cascade testing of rela-
tives. A growing consensus supports LS screening in EC; however, the expected proportion
of test positives, and optimal testing strategy is uncertain. Previous studies from insurance-
based healthcare systems were limited by narrow selection criteria, failure to apply refer-
ence standard tests consistently, and poor conversion to definitive testing. The aim of this
study was to establish the prevalence of LS and the diagnostic accuracy of LS testing strate-
gies in an unselected EC population.
Methods and findings
This was a prospective cross-sectional study carried out at a large United Kingdom gynae-
cological cancer centre between October 2015 and January 2017. Women diagnosed with
EC or atypical hyperplasia (AH) were offered LS testing. Tumours underwent MMR immu-
nohistochemistry (IHC), microsatellite instability (MSI), and targeted MLH1-methylation test-
ing. Women <50 years, with strong family histories and/or indicative tumour molecular
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features, underwent MMR germline sequencing. Somatic MMR sequencing was performed
when indicative molecular features were unexplained by LS or MLH1-hypermethylation.
The main outcome measures were the prevalence of LS in an unselected EC population
and the diagnostic accuracy of clinical and tumour testing strategies for risk stratifying
women with EC for MMR germline sequencing. In total, 500 women participated in the
study; only 2 (<1%) declined. Germline sequencing was indicated and conducted for 136
and 135 women, respectively. A total of 16/500 women (3.2%, 95% CI 1.8% to 5.1%) had
LS, and 11 more (2.2%) had MMR variants of uncertain significance. Restricting testing to
age <50 years, indicative family history (revised Bethesda guidelines or Amsterdam II crite-
ria) or endometrioid histology alone would have missed 9/16 (56%), 8/13 (62%) or 9/13
(69%), and 5/16 (31%) cases of LS, respectively. In total 132/500 tumours were MMR defi-
cient by IHC of which 83/132 (63%) had MLH1-hypermethylation, and 16/49 (33%) of the
remaining patients had LS (16/132 with MMR deficiency, 12%). MMR-IHC with targeted
MLH1-methylation testing was more discriminatory for LS than MSI with targeted methyla-
tion testing, with 100% versus 56.3% (16/16 versus 9/16) sensitivity (p = 0.016) and equal
97.5% (468/484) specificity; 64% MSI-H and 73% MMR deficient tumours unexplained by
LS or MLH1-hypermethylation had somatic MMR mutations. The main limitation of the study
was failure to conduct MMR germline sequencing for the whole study population, which
means that the sensitivity and specificity of tumour triage strategies for LS detection may be
overestimated, although the risk of LS in women with no clinical or tumour predictors is
expected to be extremely low.
Conclusions
In this study, we observed that age, family history, and histology are imprecise clinical corre-
lates of LS-EC. IHC outperformed MSI for tumour triage and reliably identified both germline
and somatic MMR mutations. The 3.2% proportion of LS-EC is similar to colorectal cancer,
supporting unselected screening of EC for LS.
Author summary
Why was this study done?
• Endometrial (womb) cancer (EC) is the most common gynaecological cancer in the
developed world, and its incidence is rising. A significant minority (around 3%) of EC
are caused by an inherited genetic predisposition called Lynch syndrome (LS).
• EC may be the first sign that a woman has LS. She is likely to survive this cancer but
develop other preventable cancers related to LS later in life. Her family members are
also at risk.
• Identifying women with LS can enable them to reduce their risk of new cancers, for
example, through bowel (colorectal) cancer surveillance (colonoscopy).
• We do not know how many women with EC have LS or how best to identify them; cur-
rent practice is based on experience in bowel cancer and may not be accurate in EC.
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What did this research do and find?
• We tested 500 women with EC treated in a large tertiary referral centre in the North
West of England for LS.
• We did not preselect women to test based on clinical or tumour characteristics. We
tested tumours for features of LS called mismatch repair (MMR) deficiency and micro-
satellite instability (MSI). Women with strongly suggestive clinical or tumour character-
istics underwent germline LS testing.
• In total, 16 of 500 women (3%) had LS, and these women could not always be predicted
by their age or family history.
• MMR deficiency was more accurate than MSI at identifying LS-EC, picking up 16/16
(100%) versus 9/16 (56%).
What do these findings mean?
• In our study, we found that 3% of women with endometrial cancer have LS and can ben-
efit from strategies to reduce their future cancer risk.
• Our results suggest that it may be best to test everyone because preselecting women to
test based on clinical or tumour characteristics misses cases of LS.
• In this population, tumour MMR deficiency was more accurate than MSI at identifying
LS in EC.
• Our results should be interpreted with caution because we did not do germline testing
on all women, and the number of women we tested was relatively small.
Introduction
Endometrial cancer (EC) is the most common gynaecological cancer in developed countries,
and incidence is rising [1]. Although mostly driven by obesity and decreased parity, a signifi-
cant minority is caused by Lynch syndrome (LS), an inherited susceptibility to defective DNA
mismatch repair (MMR). At least 1:280 of the general population carries a pathogenic variant
in an MMR gene—MLH1, MSH2, MSH6 or PMS2 (path_MMR)—the vast majority of whom
are undiagnosed [2]. The risks of EC, ovarian cancer (OC), and colorectal cancer (CRC) in
path_MMR heterozygotes are approximately 35%, 11%, and 46%, respectively [3]. These risks
are significantly higher than for the general population (EC-3%, OC-1%, and CRC-5.5%) [4].
Often the first malignancy affecting women with LS, EC provides a unique diagnostic
opportunity [5]. Most women survive EC [6] but remain at increased risk of associated can-
cers, particularly CRC [7]. Cascade testing of relatives generates on average 3 further diagnoses
per index case [8]. These path_MMR carriers can benefit from chemoprophylaxis [9], risk-
reducing surgery [10], family planning, and cancer surveillance [3]. Unselected screening of
EC for MMR deficiency and/or microsatellite instability-high (MSI-H, a hallmark of MMR
deficiency) has advantages that extend beyond LS carrier identification. Programmed cell
death protein 1 (PD-1) blockade immunotherapy is most effective in MMR deficient tumours
[11], and molecular characterization defines prognosis and treatment eligibility [12].
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Path_MMR carriers’ association with EC is well established [3]; however, the proportion of
EC patients likely to test positive for LS is uncertain, with estimates spanning <1% to>10%.
The variation in estimates comes from methodological heterogeneity, small sample sizes, and
incomplete testing [13]. Initial tumour triage by immunohistochemistry (IHC) and/or MSI
with/without MLH1-methylation testing selects women for definitive constitutional analysis
[14]. However, the diagnostic accuracy of these strategies is unknown in EC [15]. For instance,
MSI testing has reduced sensitivity in path_MSH6 tumours [16]. Selecting test populations by
age and/or family history, failure to apply reference standard tests consistently, and poor con-
version to definitive testing are all potential sources of bias [13]. Most previous studies involve
insurance-based healthcare systems; this is fraught with difficulty because fear of lack of reim-
bursement by services [17] and increased insurance premiums in individuals [18] influences
testing decisions. Thus, the aims of this prospective study were to (1) establish the prevalence
of LS and (2) evaluate the diagnostic accuracy of common LS testing strategies in an unselected
EC population within a non–insurance-based healthcare system.
Methods
Study protocol
The Proportion of Endometrial Tumours Associated with Lynch Syndrome (PETALS) study
was sponsored by the University of Manchester, United Kingdom, and approved by the North
West Research Ethics Committee (15/NW/0733; S1 Protocol). The study was prospectively
registered (Cancer Research-UK clinical trial database, ref-13595). It is reported according to
the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guide-
line (S1 Checklist), and the primary data set is also provided (S1 Data).
Participants
Women were recruited from gynaecology clinics at Manchester University NHS Foundation
Trust (MFT), a large gynaecological cancer centre, between October 2015 and January 2017.
Women diagnosed with EC or atypical hyperplasia (AH) over the preceding 5 years were eligi-
ble for recruitment without demographic or histological restrictions. AH was included to cap-
ture the full spectrum of endometrial neoplasia. All women gave written, informed consent to
participate, providing blood-DNA, tumour, and clinical data (age, body mass index [BMI],
self-reported ethnicity) including detailed family histories (pedigrees). The latter were scored
using revised Bethesda [19], Amsterdam II [20], and Prediction of MMR Gene Mutations-v.5
scores (PREMM5) [21]. Additional samples were procured from women with EC who had
consented to their clinical data, tumours, and DNA being used for future research between
2013 and 2014 at MFT; their detailed pedigrees were not available.
Somatic tumour analysis
Hysterectomy and biopsy specimens were assessed by 2 specialist gynaecological pathologists
according to FIGO-2009 staging criteria (EC) and WHO classification system (AH). Stromal
tumour-infiltrating lymphocytes (TILs) were reported as previously described [22]. Tumour
molecular profiling used the hysterectomy specimen when possible, but diagnostic endome-
trial specimens were used when hysterectomy was not performed or when equivocal IHC was
repeated. All tissue was formalin-fixed and paraffin-embedded according to local clinical pro-
tocols. Tissue blocks with the greatest tumour content (>70%) were chosen for DNA extrac-
tion. Tumour was either microdissected from 5 × 10 μm unstained sections or cored from
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tissue blocks, depending on tumour content. Nonmalignant adjacent tissue was selected for
comparative constitutional MSI analysis.
IHC. IHC for the 4 MMR proteins was performed using the automated Ventana Bench-
Mark ULTRA IHC/in situ hybridisation (ISH) staining module and the OptiView,
30diaminobenzidine version 5 detection system (Ventana Co., USA) in a laboratory that partic-
ipates successfully in external quality assurance (EQA; UK NEQAS ICC and ISH, Module 7B;
https://www.ukneqasiccish.org; S1 Text). The proportion of stained tumour epithelial compo-
nent and intensity of staining was scored by 2 expert independent observers using tumour
stroma as internal control as previously described [23]. Examples of complete and ‘patchy’
MMR protein loss are illustrated in S1 Text.
MSI. MSI (and MLH1-methylation) analysis was performed in a UKAS ISO15189-accre-
dited MSI testing reference laboratory that successfully participates in EQA (https://www.
genqa.org). DNA was extracted and underwent sodium bisulfite conversion using the Epitect
Plus FFPE kit (Qiagen, UK). The MSI analysis system version 1.2 (Promega, USA) was used
with standardised clinical protocols. Fluorescent-labelled primers were used to co-amplify 7
markers, including 5 mononucleotide-repeat markers (BAT-25, BAT-26, NR-21, NR-24, and
MONO-27), and 2 control pentanucleotide-repeat markers (Penta-C/Penta-D). MSI status
was determined by 2 independent scientists. Identical fragment profiles between tumour and
matched normal tissue for all 5 mononucleotide loci was considered microsatellite stable
(MSS); discordance in one mononucleotide locus was MSI low (MSI-L). Discordance in 2 or
more mononucleotide loci was MSI high (MSI-H). Only those with MSI-H tumours were con-
sidered at risk of LS; this is consistent with expert consensus [15].
Methylation analysis. Reflex MLH1-methylation testing was performed on MLH1 and/or
PMS2-deficient and/or MSI tumours as previously described [24]. Purified DNA was ampli-
fied with bisulfite specific primers in triplicate. An MLH1 promoter region containing 4 CpG
dinucleotides whose methylation status is strongly correlated with MLH1 expression was ana-
lysed using pyrosequencing (PSQ 96MA). Two independent scientists interpreted the pyro-
grams. ‘Hypermethylation’ described >10% mean methylation across the 4 CpG dinucleotides
on over two-thirds of replicate analyses. A proportion of MLH1-hypermethylation cases
underwent reference standard germline MMR sequencing to exclude co-existing path_MLH1
variants.
Germline analysis
Indications for germline analysis were age<50 years; meeting revised Bethesda guidelines/
Amsterdam II criteria; PREMM5 score >10%; and indicative tumour molecular features, spe-
cifically MMR deficiency (MMRd, tumour epithelial loss of�1 MMR protein on IHC) and/or
MSI-H unexplained by somatic MLH1-hypermethylation.
DNA was extracted from 2 mL lymphocyte blood (ethylenediaminetetraacetic acid [EDTA]
anticoagulant) using Chemagic DNA blood chemistry (CMG-1097-D) on an automated Per-
kin Elmer Chemagic-360 Magnetic Separation Module and a JANUS Integrator 4-tip Auto-
mated Liquid handling platform. DNA was eluted into 400 μL buffer. The concentration and
quality of extracted DNA samples were measured using a Nanodrop ND-8000 spectrophotom-
eter. MMR genes MLH1, MSH2, and MSH6 were amplified using long-range polymerase
chain reaction (PCR) followed by next generation sequencing (NGS) using Illumina SBS ver-
sion 2 2 × 150 bp and Illumina MiSeq to analyse the coding region, flanking sequences to ±15
bp and known splicing variants (minimum 100× coverage depth) of MLH1, MSH2, and MSH6
(S1 Text). Variant identification and calling was via an in-house bioinformatic pipeline.
Reported sequence changes and regions with<100× coverage were retested via Sanger
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sequencing using BigDye version 3.1. Copy number analysis to detect large genomic rear-
rangements affecting the MMR genes was performed using MLPA MRC-Holland probe
mixes: P003-D1 MLH1/MSH2 and P072-C1 MSH6. Variant nomenclature followed Human
Genome Variation Society (HGVS) guidelines (http://www.hgvs.org/vamomen) using refer-
ence sequences: LRG_216,t1(MLH1); LRG_218,t1(MSH2); LRG_219,t1(MSH6). Exons were
numbered consecutively starting from exon 1 as the first translated exon for each probe mix.
Cases with PMS2 protein loss, normal MLH1-methylation, and no path_MLH1/MSH2/MSH6
variant underwent path_PMS2 analysis at the regional specialist Yorkshire and North East
Genomic Laboratory. When pathogenicity of the variant was unclear, Ian Frayling was con-
sulted as InSiGHT representative to adjudicate. Somatic MMR sequencing was performed for
discordant tumour/germline results (S1 Text).
Statistical analysis
We determined that a sample size of 497 was required to find a prevalence of LS-EC of 3%
(95% confidence intervals 1.5%–4.5%) [25]. The statistical analysis plan was devised a priori.
Diagnostic accuracy measures were conducted to establish the utility of clinical parameters
and tumour triage strategies for risk stratifying women with EC for MMR germline sequenc-
ing, including age, family history, histological subtype, density of TILs, MMR deficiency by
IHC, MSI status, and MLH1-methylation status. There were no data-driven changes to analy-
ses. Descriptive univariate analysis was performed using Student t test or two-way ANOVA for
normally distributed continuous variables, and Mann–Whitney U test for non-normally dis-
tributed continuous variables. Normality of the data was assessed by the Belanger and D’Agos-
tino method with the Royston adjustment (alpha = 0.05) [26]. Pearson’s chi-squared test was
used to test for independence of categorical variables. Diagnostic accuracy measures (sensitiv-
ity, specificity, and positive and negative predictive values) were calculated using standard for-
mulae, with confidence intervals estimated by the Clopper–Pearson method. The reference
standard was germline analysis and only women with path_MMR variants (not variants of
unknown significance [VUS]) were considered to have LS (disease positive). Women were
treated as disease negative (no LS) when germline analysis was not indicated. The exact McNe-
mar’s test was used to compare the sensitivity and specificity of IHC-based versus MSI-based
testing for LS identification. Logistic regression was used to identify clinical predictors of MSI,
MMR deficiency, MLH1-hypermethylation, and germline path_MMR variants.
Results
Study population
In total, 305 women were invited to participate in PETALS and undergo testing for LS (pedigree
cohort). Only 2 declined, and 3 were ineligible (not EC/AH on final pathology; Fig 1). A further
200 women treated for AH/EC at MFT in the preceding 2 years (2013–2014) were included, but
detailed family histories were unavailable (nonpedigree cohort). The final study population
comprised 500 women with median age and BMI of 65-years and 32kg/m2, respectively, of pre-
dominantly white British ethnicity (81%; Table 1). There were 470 EC cases (94%) and 30 AH
(6%). Most EC were low grade (62%) and early stage tumours (72%) of endometrioid subtype
(70%). All 500 women underwent both MMR-IHC and MSI analysis, with targeted MLH1-
methylation testing. Of these, 135 women underwent germline LS testing for the following indi-
cations: MSI-H MMR deficient tumour with normal MLH1-methylation (n = 6); MSI-H MMR
deficient tumour (MLH1-methylation testing not indicated; n = 13); MMR deficient and MSS/
MSI-L (n = 19); MSI-H MMR-proficient tumour (n = 6); age�50 years (n = 35); and strong
family history (n = 12). A subset of women with tumour MLH1-hypermethylation (n = 26) and
PLOS MEDICINE The proportion of endometrial tumours associated with Lynch syndrome (PETALS)
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1003263 September 17, 2020 6 / 19
Fig 1. Study flow diagram. Methylation testing only done if�1 of MLH1 or PMS2 was lost on immunohistochemistry. “No methylation” denotes it
was not indicated. #PMS2 only tested if PMS2d and no path_MLH1, path_MSH2 or path_MSH6. ^One of the MSI-H samples did not undergo
germline testing as the patient died before blood could be taken. MSI, microsatellite instability; MSS, microsatellite stable; MMR, mismatch repair;
MMRp, MMR proficient (no MMR protein loss); MMRd, MMR deficient (�1 MMR protein lost).
https://doi.org/10.1371/journal.pmed.1003263.g001
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Table 1. Patient demographics and clinical characteristics.
Patient characteristics Overall (n = 500) Pedigree cohort (n = 300) Nonpedigree cohort (n = 200) P valuea
Age, years [median (IQR)] 65 (56–73) 65 (56–73) 65 (56–72.5) 0.72b
>80 30 (6.0%) 15 (5.0%) 15 (7.5%)
60–80 295 (59.0%) 179 (59.7%) 116 (58.0%)
51–59 102 (20.4%) 63 (21.0%) 39 (19.5%)
�50 73 (14.6%) 43 (14.3%) 30 (15.0%)
Ethnicity 0.055c
White 405 (81.0%) 248 (82.7%) 157 (78.5%)
Black 20 (4.0%) 10 (3.3%) 10 (5.0%)
Asian 55 (11.0%) 30 (10.0%) 25 (12.5%)
Chinese 10 (2.0%) 3 (1.0%) 7 (3.5%)
Other 10 (2.0%) 9 (3.0%) 1 (0.5%)
BMI, kg/m2 [median, range] 31.6 (16.6–71.0) 31.3 (16.8–69.5) 32.0 (16.6–71.0) 0.11b
Underweight [0–18.5] 5 (1.0%) 2 (0.7%) 3 (1.5%)
Normal [18.5–25] 89 (17.9%) 62 (20.7%) 27 (13.6%)
Overweight [25–30] 109 (21.9%) 62 (20.7%) 47 (23.7%)
Obese Class I [30–35] 111 (22.3%) 69 (23.0%) 42 (21.2%)
Obese Class II [35–40] 67 (13.5%) 44 (14.7%) 23 (11.6%)
Obese Class III [40–45] 46 (9.2%) 23 (7.7%) 23 (11.6%)
Obese Class IV [45–50] 25 (5.0%) 17 (5.7%) 8 (4.0%)
Obese Class V [50–60] 34 (6.8%) 17 (5.7%) 17 (8.6%)
Obese Class VI [�60] 12 (2.4%) 3 (1.3%) 8 (4.0%)
Grade of tumour 0.001c�
Atypical hyperplasia 30 (6.0%) 8 (2.7%) 22 (11.0%)
1 209 (41.8%) 134 (44.7%) 75 (37.5%)
2 101 (20.2%) 58 (19.3%) 43 (21.5%)
3 160 (32.0%) 100 (33.3%) 60 (30.0%)
FIGO (2009) stage <0.001c�
Atypical hyperplasia 30 (6.0%) 8 (2.7%) 22 (11.0%)
I 360 (72.0%) 221 (73.7%) 139 (69.5%)
II 48 (9.6%) 37 (12.3%) 11 (5.5%)
III 59 (11.8%) 32 (10.7%) 27 (13.5%)
IV 3 (0.6%) 2 (0.7%) 1 (0.5%)
Histological subtype 0.001c�
Atypical hyperplasia 30 (6.0%) 8 (2.7%) 22 (11.0%)
Endometrioid 351 (70.2%) 214 (71.3%) 137 (68.5%)
Serous 33 (6.6%) 28 (9.3%) 5 (2.5%)
Clear cell 23 (4.6%) 13 (4.3%) 10 (5.0%)
Carcinosarcoma 34 (6.8%) 21 (7.0%) 13 (6.5%)
Dedifferentiated 10 (2.0%) 6 (2.0%) 4 (2.0%)
Mixed 19 (3.8%) 10 (3.3%) 9 (4.5%)
Sample type 0.017c�
Biopsy 44 (8.8%) 19 (6.3%) 25 (12.5%)
Hysterectomy 456 (91.2%) 281 (93.7%) 175 (87.5%)
aP value compares pedigree and nonpedigree cohorts.
bP value from Mann–Whitney U test.
cP value from Pearson’s χ2 test.
�Denotes statistical significance at alpha = 0.05.
Abbreviations: BMI, body mass index; FIGO, International Federation of Gynecology and Obstetrics; IQR, interquartile range
https://doi.org/10.1371/journal.pmed.1003263.t001
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subset of MSS/MSI-L patchy tumour MMR deficiency (n = 18) also underwent testing (see
Fig 1).
Proportion of tumours associated with LS
We identified 16 path_MMR variant carriers, giving a 3.2% overall LS prevalence (95% CI
1.84%–5.14%). There were 8 path_MSH6, 4 path_MSH2, 2 path_MLH1, and 2 path_PMS2 var-
iant carriers (Table 2). Three had known LS, 2 died shortly after EC diagnosis, and the remain-
ing 11 were offered, of whom 10 accepted, genetic counselling. To date, 14 relatives have also
received genetic counselling. One woman carried 2 VUS_MSH6, considered pathogenic in
combination (S2 Text). A further 10 women had MMR variants that were not recognized by
InSiGHT (https://www.insight-group.org), including 5 previously unreported variants (S3
Text). Greatest discrepancy between IHC and MSI findings was observed for those with a
germline path_MSH6 variant with 5/8 demonstrating MSH6 loss on IHC but MSS. One
path_MSH6 variant (MSH6 c.2731C>T p.(Arg911Ter) was observed in 3 index cases and
therefore could represent a local founder mutation; however, review of the local clinical data-
base indicates this variant only affects 5/487 of local LS families.
Selecting women for germline LS testing
Age and family history. In total, there were 73 women�50 years, of whom 7 (10%) had
LS. All 7 had indicative tumour molecular features (MMRd ± MSI-H). Only screening women
<50,<60, and<70 years would have missed 9, 6, and one LS diagnosis, respectively (Table 3).
A further 35 women <50 years with MSS/MSI-L MMR-proficient tumours underwent germ-
line testing for LS; 4 (11.4%) had VUS_MMR, but no further path_MMR variants were
identified.
Comprehensive pedigree data were available for 300 women. Only 7/300 (2%) and 9/300
(3%) women with detailed pedigrees met the Amsterdam II criteria and revised Bethesda
guidelines, of whom 4 (57%) and 5 (56%) had LS, respectively. All women with LS also had
indicative tumour molecular features. The overall mean PREMM5 score was 3.2% (SD 2.4%).
A total of 164/299 (55%) women had scores greater than the 2.5% recommended cut-off for
germline testing, with mean PREMM5 score 4.3% in this subgroup, and 11 (6.7%) having LS.
An additional 12 women with MSS/MSI-L MMR-proficient tumours underwent germline
testing because of a previous LS-associated cancer (n = 3) or an indicative family history
(including Amsterdam II [n = 2], revised Bethesda [n = 4], and PREMM5 > 10% [n = 3]).
None carried a path_MMR variant or VUS_MMR.
MMR deficiency by IHC. In total 132/500 (26%) tumours were MMR deficient (Table 4),
of which 83 were MSI-H. Women with MMR deficient tumours were older than those without
MMR loss (mean difference 3.3 years, t test [unequal variances] p = 0.007). Of the 24 women
who had tumours with patchy MMR loss, one had a germline VUS_MMR but none had LS.
One MSS AH case had patchy MSH6 loss and was subsequently found to have a VUS_MSH6,
but all other AH samples had intact MMR. Thirteen tumours failed first attempt but not repeat
MMR-IHC testing.
MSI analysis. In total, 89/500 (18%) tumours were MSI-H, and 21/500 (4%) were MSI-L.
None of the 6 MSI-H MMR-proficient tumours were LS-associated (Table 4). Women with
MSI-H tumours were older than those with MSS tumours (mean difference 4.7 years,
p< 0.001). Mononucleotides BAT-25 and/or BAT-26 accounted for 95% of MSI-H events. No
AH samples were MSI-H. Eights tumours failed first attempt but not repeat MSI analysis.
MLH1-methylation analysis. In total, 100 tumours underwent reflex MLH1-methylation
analysis because of MLH1-deficiency on IHC. Of these, 83 (16% of 500) were hypermethylated
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Table 2. Clinicopathological characteristics, tumour-based triage, and germline sequencing results of women with LS-associated EC.
Patient Demographics Family history Pathology Tumour-based triage Germline sequencing
ID Age
range
(y)
BMI
(kg/
m2)
Ethnicity Meets
Amsterdam
II Criteria
Meets
Revised
Bethesda
Criteria
PREMM5
score
FIGO (2009)
stage, grade and
histological
subtype
MMR-IHC
results
MSI
results
Germline
pathological variant
InSiGHT
class
ACMG
class
16a 30–34 23 White Yes Yes 17.80% Stage 1a grade 3
mixed
endometrioid
and clear cell EC
MLH1/PMS2
loss
(normal
MLH1-
methylation)
MSI-H MLH1 c.473delA p.
(Asn158ThrfsTer2)
5� P
25 50–54 30 White Yes Yes 7.60% Stage 3b grade 2
endometrioid
EC
MSH2/
MSH6 loss
MSI-H MSH2 c.2563C>T p.
(Gln855Ter)
5 P
31a 40–44 25 White No No 9.10% Stage 1a grade 1
endometrioid
EC
Isolated
MSH6 loss
MSS MSH6 c.2731C>T p.
(Arg911Ter)
5 P
61 45–49 42 Asian Yes Yes 24.20% Stage 3a grade 3
de-differentiated
EC
MSH2/
MSH6 loss
MSI-H MSH2 Ex n7
deletion
5 P
96 80–84 29 White No No 2.00% Stage 3b grade 2
endometrioid
EC
Isolated
MSH6 loss
MSS MSH6 c.1084C>T p.
(Pro362Ser) & MSH6
c.2018C>T p.
(Pro673Leu)
4� VUS
122 45–49 20 White No No 11.30% Stage 1a grade 1
endometrioid
EC
MSH2/
MSH6 loss
MSI-H MSH2 c.366+1G>A 4 P
128 60–64 23 White No No 2.50% Stage 1b grade 1
endometrioid
EC
Isolated
MSH6 loss
MSI-L MSH6 c.3313G>T p.
(Gly1105Ter)
5� LP
173 65–69 23 White No No 2.20% Stage 1a grade 2
endometrioid
EC
PMS2 loss MSI-H PMS2 Del Exon 9–10 5 P
213 44–49 27 White No No 4.80% Stage 2 grade 3
mixed
endometrioid
and clear cell EC
Isolated
MSH6 loss
MSI-H MSH6 c.2731C>T p.
(Arg911Ter)
5 P
215 60–64 33 White No No 2.50% Stage 3b grade 2
endometrioid
EC
Isolated
MSH6 loss
MSI-H MSH6
c.3004_3005delGG p.
(Gly1002LeufsTer2)
5� P
241 60–64 36 White No No 3.10% Stage 1b grade 3
carcinosarcoma
Isolated
MSH6 loss
MSI-H MSH6 c.2731C>T p.
(Arg911Ter)
5 P
255 55–59 34 White No No 6.40% Stage 1a grade 3
endometrioid
EC
Isolated
MSH6 loss
MSS MSH6 c.2731C>T p.
(Arg911Ter)
5 P
256a,b 45–49 32 White Yes Yes 8.60% Stage 1a grade 1
endometrioid
EC
MLH1/PMS2
loss
(normal
MLH1-
methylation)
MSI-H MLH1 c.1409+1
G>C
5 P
BRC
882
25–29 21 Asian No Yes 27.20% Stage 1a grade 1
endometrioid
EC
Isolated
PMS2 loss
MSS Homozygous PMS2
c.1500delC
5� P
BRC
165
65–69 23 White No No 3.00% Stage 3a grade 3
carcinosarcoma
MSH2/
MSH6 loss
MSS MSH2 Del Exon 1–8 5 P
(Continued)
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(Table 4), and none of the 26 hypermethylated cases (31%) who underwent germline analysis
had LS. One sample failed MLH1-methylation analysis several times. Women with MLH1-
hypermethylated tumours were older than those with MMR-proficient tumours (t test
[unequal variance] p< 0.001) and those with normal MLH1-methylation MMR deficient
tumours (t test [unequal variance] p = 0.0034). Of 15 women with normal MLH1-methylation
MMR deficient tumours, 3 (20%) had LS, all of which had complete IHC loss (3/10, 30%).
Table 2. (Continued)
Patient Demographics Family history Pathology Tumour-based triage Germline sequencing
ID Age
range
(y)
BMI
(kg/
m2)
Ethnicity Meets
Amsterdam
II Criteria
Meets
Revised
Bethesda
Criteria
PREMM5
score
FIGO (2009)
stage, grade and
histological
subtype
MMR-IHC
results
MSI
results
Germline
pathological variant
InSiGHT
class
ACMG
class
PRE
011
55–59 30 White No No 3% Stage 1a grade 1
endometrioid
EC
Isolated
MSH6 loss
MSS MSH6 c.3261delC p.
(Phe1088SerfsTer2)
5 P
aAlready aware of LS diagnosis before enrolment in PETALS study.
bEnrolled in gynaecological cancer surveillance program, EC incidental finding at risk reducing prophylactic hysterectomy.
InSiGHT: class 5, pathogenic MMR variant; class 4, likely pathogenic MMR variant; class 3, MMR variant of uncertain pathogenicity.
ACMG classification of MMR variants: P, pathogenic; LP, likely pathogenic; VUS, variant of uncertain significance.
Abbreviations: ACMG, American College of Medical Genetics and Genomics; BMI, body mass index; EC, endometrial cancer; FIGO,; IHC, immunohistochemistry;
InSiGHT,; LS, Lynch Syndrome; MMR, mismatch repair; MSI, microsatellite instability; MSI-H, microsatellite instability-high; MSI-L, microsatellite instability-low;
MSS, microsatellite stable; PREMM5, Prediction of MMR Gene Mutations-v.5 scores
https://doi.org/10.1371/journal.pmed.1003263.t002
Table 3. Diagnostic test accuracy of clinicopathological selection criteria and tumour-based triage strategies.
Clinicopathological variable Sensitivity (%) Specificity (%) PPV (%) NPV (%)
MMR deficiency by IHC 100 (79.4–100) 80.6 (76.8–84.0) 14.5 (8.5–22.5) 100 (99.1–100)
With MLH1-methylation testing 100 (79.4–100) 96.7 (94.7–98.1) 50.0 (31.9–68.1) 100 (99.2–100)
MSI-H 56.3 (29.9–80.2) 83.5 (79.9–86.7) 10.1 (4.7–18.3) 98.3 (96.5–99.3)
With MLH1-methylation testing 56.3 (29.9–80.2) 96.7 (94.7–98.1) 36.0 (18.0–57.5) 98.5 (97.0–99.4)
MMR deficiency or MSI-H 100 (79.4–100) 79.1 (75.2–82.7) 13.7 (8.0–21.3) 100 (99.0–100)
With MLH1-methylation testing 100 (79.4–100) 95.5 (93.2–97.1) 42.1 (26.3–59.2) 100 (99.2–100)
Age
<50 years 43.8 (19.8–70.1) 87.4 (84.1–90.2) 10.3 (4.2–20.1) 97.9 (96.1–99.0)
<60 years 56.3 (29.9–80.2) 65.7 (61.3–69.9) 5.1 (2.4–9.5) 97.8 (95.6–99.1)
<70 years 93.8 (69.8–99.8) 35.1 (30.9–39.6) 4.6 (2.6–7.4) 99.4 (96.8–100.0)
BMI <35 kg/m2 86.7 (59.5–98.3) 37.7 (33.3–42.2) 4.1 (2.2–7.0) 98.9 (96.1–99.9)
<50 years 33.3 (11.8–61.6) 94.8 (92.5–96.6) 16.7 (5.6–34.7) 97.9 (96.1–99.0)
<60 years 46.7 (21.3–73.4) 82.0 (78.3–85.3) 7.4 (3.0–14.7) 98.0 (96.1–99.1)
<70 years 80.0 (51.9–95.7) 64.0 (59.5–68.3) 6.5 (3.4–11.0) 99.0 (97.2–99.8)
PREMM5 score 84.6 (54.6–98.1) 46.5 (40.6–52.5) 6.7 (3.4–11.7) 98.5 (94.8–99.8)
Amsterdam II Criteria 30.8 (9.1–61.4) 99.0 (97.0–99.8) 57.1 (18.4–90.1) 96.9 (94.2–98.6)
Revised Bethesda Guidelines 38.5 (13.9–68.4) 98.6 (96.5–99.6) 55.6 (21.2–86.3) 97.3 (94.7–98.8)
Endometrioid histopathology 68.8 (41.3–88.9) 29.8 (25.7–34.0 3.1 (1.6–5.5) 96.6 (92.3–98.9)
High TILs 93.8 (69.8–99.8) 76.7 (72.6–80.4) 11.7 (6.7–18.6) 99.7 (98.5–100)
Abbreviations: BMI, body mass index; IHC, immunohistochemistry; MMR, mismatch repair; MSI, microsatellite instability; MSI-H, microsatellite instability-high;
NPV, negative predictive value; PPV, positive predictive value; PREMM, PREdiction Model for gene Mutations; TIL, tumour-infiltrating lymphocyte
https://doi.org/10.1371/journal.pmed.1003263.t003
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Table 4. Molecular analysis of MMR deficient, MLH1-hypermethylated, and MSI-H tumours.
Tumour
characteristic
n MSI-H MSI-L MLH1-
hypermethylated
path_MMR
variant
VUS_MMR Somatic MMR
mutation
Unexplained when all
tests completed
%
unexplained
MMR proficient 368 7a 18 N/A 0 4 N/A N/A N/A
MMR deficient 132b 81 3 82e 16 7 16c,d 16/127f,g 12.6%
Complete MMR deficiency
Overall 108b 80 2 77 16 6 12c 2/106f 1.9%
MLH1 only 2 2 0 2 0 0 N/A 0/2 0%
MLH1 and PMS2 82 65 2 75 2 2 2 0/80f 0%
PMS2 only 2 0 0 0 2 0 N/A 0/2 0%
MSH2 only 0 0 0 0 0 0 N/A N/A N/A
MSH2 and MSH6 9 7 0 0 4 1 4 1/9 11%
MSH6 only 12 5 0 0 8 2 6 1/12 8.5%
MLH1 and PMS2
and MSH6
1 1 0 1 0 1 0 0/1 0%
Patchy MMR deficiency
Overall 24 1 1 5e 0 1 4d 14/21g 67%
MLH1 only 4 1 0 2 0 0 0 2/4 50%
MLH1 and PMS2 13 0 1 3 0 0 1 6/10g 60%
PMS2 only 2 0 0 0 0 0 0 2/2 100%
MSH2 only 1 0 0 0 0 0 1 0/1 N/A
MSH2 and MSH6 2 0 0 0 0 0 2 2/2 100%
MSH6 only 2 0 0 0 0 1 0 1/2 50%
MLH1-
hypermethylated
83e 64 1 0 0 0
Complete MMR deficiency
Overall 78 63 1 N/A 0 0
MLH1 only 2 2 0 N/A 0 0
MLH1 and PMS2 75 61 1 N/A 0 0
PMS2 only 1 0 0 N/A 0 0
MLH1 and PMS2
and MSH6
1 1 0 N/A 0 0
Patchy MMR deficiency
Overall 5e 1 0 N/A 0 0
MLH1 only 2 1 0 N/A 0 0
MLH1 and PMS2 3 0 0 N/A 0 0
PMS2 only 0 0 0 N/A 0 0
Normal MLH1-
methylation
16h 6 1 N/A 3 3
Complete MMR deficiency
Overall 9 6 0 N/A 3 2
MLH1 only 0 0 0 N/A 0 0
MLH1 and PMS2 8 6 0 N/A 2 2
PMS2 only 1 0 0 N/A 1 0
MLH1 and PMS2
and MSH6
0 0 0 N/A 0 0
Patchy MMR deficiency
Overall 6 0 1 N/A 0 1
MLH1 only 1 0 0 N/A 0 0
(Continued)
PLOS MEDICINE The proportion of endometrial tumours associated with Lynch syndrome (PETALS)
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1003263 September 17, 2020 12 / 19
Somatic MMR sequencing
Somatic MMR testing was performed when indicative tumour molecular features were
unexplained by LS or MLH1-hypermethylation: MSI-H MMR deficient (n = 8), MSS/MSI-L
MMR deficient (n = 7), MSI-H MMR-proficient (n = 6), patchy MMR deficient (n = 18), and
germline VUS_MMR (n = 1) cases (S4 Text). Six tumours failed (MSI-H MMR deficient
[n = 2], MSI-H MMR-proficient [n = 1], and patchy MMR deficient [n = 3] cases). This com-
prehensive testing left just 1.9% (2/106) MMR deficient tumours unexplained by a path_MMR
variant/epigenetic silencing (Table 4).
Diagnostic test accuracy of tumour triage
MMR-IHC was superior to MSI analysis for the identification of LS (Table 3). Sensitivity and
specificity were 100% versus 56.3% (16/16 versus 9/16; difference 43.75%, 95% CI 13.2%–
74.3%, p = 0.016) and 80.6% versus 83.5% (390/484 versus 404/484; difference −2.9%, 95% CI
−5.2% to −0.6%, p = 0.013), respectively. Specificity was increased to 97.7% for both
MMR-IHC and MSI with reflex MLH1-methylation testing (p = 1). The area under the ROC
curve for PREMM5 and age was 0.73 versus 0.71, respectively, with PREMM5 superior to age,
although neither matched MMR-IHC for selecting women for germline LS testing (S5 Text).
Eleven LS-associated tumours (69%) were of pure endometrioid histotype, and 15 (94%) had
high tumour-infiltrating lymphocyte counts. MMR germline sequencing was conducted for
135/500 women, which means that the sensitivity and specificity of tumour triage strategies for
LS detection may be overestimated in this study, although the risk of LS in women with no
clinical or tumour predictors is expected to be extremely low.
Clinical predictors of test outcomes
Increased age was positively associated with tumour MMR deficiency (OR 1.02, 95% CI 1.00–
1.04, p = 0.013), MSI-H (OR 1.03, 95% CI 1.01–1.05, p = 0.003), and MLH1-hypermethylation
(OR 1.04, 95% CI 1.02–1.06, p< 0.001) (tumours in which methylation testing was not indi-
cated were assumed to have normal MLH1 methylation), whilst negatively associated with LS
(0.95, 95% CI 0.92–0.99, p = 0.006). PREMM5 was positively associated with LS (OR 3.88, 95%
CI 1.74–8.65, p = 0.001) but not with tumour test outcomes (IHC, MSI, or MLH1-hypermethy-
lation). BMI was negatively associated with MMR deficiency (OR 0.98, 95% CI 0.96–1.00,
Table 4. (Continued)
Tumour
characteristic
n MSI-H MSI-L MLH1-
hypermethylated
path_MMR
variant
VUS_MMR Somatic MMR
mutation
Unexplained when all
tests completed
%
unexplained
MLH1 and PMS2 4 0 1 N/A 0 1
PMS2 only 1 0 0 N/A 0 0
aOne of the MSI-H samples did not undergo germline testing as the patient died before blood could be taken.
bOne sample defined as inconclusive IHC loss after MDT review.
cIncludes one mono-allelic without loss of heterogeneity VUS.
dIncludes 2 mono-allelic without loss of heterogeneity VUS.
eOne sample failed methylation analysis multiple times.
fTwo complete MMRd samples failed somatic analysis (both MLH1/PMS2 loss).
gThree ‘patchy’ MMRd samples failed somatic analysis (all MLH1/PMS2 IHC loss).
hOne sample (ID R125) underwent MLH1-methylation analysis on the initial interpretation of IHC loss in MLH1; this was then revised by the MDT to no loss.
Abbreviations: IHC, immunohistochemistry; MDT, multidisciplinary team; MMR, mismatch repair; MMRd, mismatch repair deficient on IHC; MSI-H, microsatellite
instability-high; MSI-L, microsatellite instability-low; N/A, not applicable; VUS, variant of unknown significance
https://doi.org/10.1371/journal.pmed.1003263.t004
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p = 0.036) and marginally negatively associated with LS (OR 0.93, 95% CI 0.87–1.00,
p = 0.055). Smoking was not consistently associated with any test outcomes.
Discussion
In this prospective study, we found a 3.2% prevalence of LS in an unselected EC population
and established MMR-IHC with targeted MLH1-methylation testing as the most accurate
method of selecting women for germline LS testing. MSI was insufficiently sensitive, missing
nearly half of all LS-EC. Family history by PREMM5 score showed excellent sensitivity but
poor specificity; the reverse was true for Amsterdam II criteria/revised Bethesda guidelines.
Restricting testing to women <60 years would miss a third of all LS cases, but only one case
was>70 years.
The 3.2% prevalence of LS-EC is consistent with the results of our recent systematic review
[13]. Only 6 previous studies tested unselected EC populations of�500 women for LS, all of
which were conducted in the insurance-based healthcare systems of the US and Australia [27–
32]. This impacted both the proportion of eligible women consenting to study participation as
well as their willingness to undergo definitive germline testing [17]. To our knowledge, this is
the first unselected EC population-based study of LS testing conducted in the fully state-funded
healthcare system of the UK. We recruited>99% of newly diagnosed EC patients attending our
institution during the recruitment period, all tumours underwent both IHC and MSI analysis,
and germline LS testing was conducted for 135/136 eligible women. We found MSI analysis had
a poor sensitivity, most notably in path_MSH6 carriers. This phenomenon has been described
previously [16]; however, no large EC studies to date have germline tested all women with both
MMR deficient and MSI-H tumours to enable a direct comparison between the 2 tumour triage
strategies [13]. For example, Goodfellow and colleagues carried out germline LS testing on just
5% of their population-based cohort, including those with MSH6-deficient MSI-H tumours
(15/107 MMR deficient tumours with normal MLH1 methylation) but not MSH6-deficient
MSI-L or MSS tumours (6/107); it is therefore not possible to calculate the sensitivity of MSI
analysis for path_MSH6 carriers from these data [29]. Hampel and colleagues found all 6 endo-
metrial tumours from path_MSH6 carriers were MMR deficient, but just 3/6 were MSI-H;
despite this, tumours were triaged for MMR germline sequencing using the results of MSI anal-
ysis, and only a subset underwent MMR-IHC [8]. Our comprehensive testing strategy also iden-
tified somatic path_MMR variants in MMR deficient and/or MSI-H tumours unexplained by
LS. This had been noted to a lesser extent in previous studies [33,34] and is an important finding
because it removes many of the tumours that would otherwise have been considered ‘Lynch-
like’ and posed a clinical management dilemma [35].
There were 5 key strengths to our study. First, we recruited 99% of eligible women, ensuring
an unbiased population of consecutive patients unrestricted by age, histological subtype, or
treatment modality. Recruitment rates of around 50% have been reported previously, mainly
from insurance-based healthcare systems [28]. Second, all tumours underwent MMR-IHC,
MSI, and targeted MLH1-methylation testing, and all but one woman with indicative tumour
features underwent germline path_MMR testing. This compares favourably to most studies
with incomplete testing [13] and allowed us to test selection criteria and tumour-based triage
strategies. Third, all analyses were carried out to quality-assured clinical standards in specialist
pathology and genetics referral laboratories. Fourth, all but 2 of the 106 (1.9%) MMR deficient
tumours were explained by MLH1-hypermethylation, somatic MMR mutation, or LS. Fifth,
our inclusion of AH, part of the spectrum of LS-EC [36], is unusual but justified because iden-
tifying LS in women with AH not only supports future risk-reducing interventions but also
impacts their immediate treatment decisions.
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The main limitation was failure to conduct germline LS sequencing on the whole study
population. In total, 135/500 (27%) women underwent germline testing, including every
woman with established clinical (age�50 years, positive family history) or tumour characteris-
tics (MMR deficient or MSI-H unexplained by MLH1-hypermethylation) predictive of LS; thus
the prevalence of LS in the 365 (73%) women who did not undergo germline LS sequencing is
expected to be extremely low. Further, our 27% germline sequencing rate is considerably higher
than that reported by other population-based studies in EC [13]. Other limitations include the
small sample size with concomitantly few LS diagnoses and correspondingly wide CIs around
our sensitivity and specificity estimates. Nevertheless, our study was large enough to detect a sig-
nificant difference in sensitivity between MMR deficiency and MSI-based tumour triage. All
women were treated at one gynaecological cancer centre in North West England; although this
might hinder generalizability to other populations, the clinicopathological characteristics of our
EC population reflect the UK national picture. The relatively high proportion of path_MSH6
variant carriers in our cohort affected the sensitivity of MSI-based tumour triage, and our study
may underestimate its true value within a wider geographical distribution, although 2 women
with path_MSH2 and homozygous path_PMS2 variants also demonstrated MSS tumour pheno-
types. Pedigree data were not available for all patients and were self-reported and therefore
prone to error, mirroring the situation in routine clinical practice.
Our findings support the unselected screening of EC for LS. We show that age, family his-
tory, and pathological findings are of limited value in selecting women for testing. Universal
germline testing is not financially feasible [37], mandating tumour-based triage. How best to
achieve this is contentious, but the prevailing wisdom is that MSI and IHC are equivalent [29],
despite limited evidence to support this [15]. Our data provide strong evidence that
MMR-IHC with targeted MLH1-methylation testing is superior to MSI-based testing in EC. It
reduces the proportion of women requiring germline sequencing without missing any cases,
lowering costs [37], and improving cost-effectiveness [38, 39]. The identification of MMR defi-
cient EC is of clinical importance. It allows clinicians to tailor treatments [40], explain progno-
sis [40], predict cancer recurrence [41], and individualize follow-up [41]. Furthermore,
women want to be tested; it is striking that 99% of eligible women approached during routine
gynaecological cancer care agreed to participate, and 10/11 newly identified LS carriers
attended genetic counselling and supported cascade testing of at-risk family members.
Unselected screening of EC for LS leads to the discovery of VUS_MMR. These create a clin-
ical conundrum because new variants can be challenging to classify. Indeed, 15 of our 27
MMR variants were not previously reported to either the ClinVar or InSiGHT data sets. This
highlights the need for international multidisciplinary expert teams to explore the clinical sig-
nificance of VUS_MMR and/or investment in saturation genome editing platforms for high
throughput analysis [15]. Such infrastructure is established for MMR variant interpretation
and behoves all clinical laboratories to interpret variants according to a single set of defined
criteria (https://www.insight-group.org/criteria/) before universal screening for LS in EC
begins in earnest.
To our knowledge, this is the most comprehensive study to date exploring the prevalence of
LS in an unselected EC population treated within a non–insurance-based healthcare system.
Consent for LS testing was taken by gynaecologists during routine clinical care [42]. In this
cohort, we found IHC outperforms MSI as a means of tumour-based triage and reliably identi-
fies both germline and somatic MMR deficient tumours to inform clinical care. The overall
prevalence of LS in EC was 3.2%, which is comparable to that of CRC [30], and justifies a simi-
lar recommendation for unselected LS screening. We endorse, when resources allow, the uni-
versal screening of EC for LS using IHC, targeted MLH1-methylation testing, and, where
indicated, germline sequencing for path_MMR variants.
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